Dr. Rudin Discusses the Success of Immunotherapy in SCLC

Charles M. Rudin, MD, PhD
Published: Tuesday, Oct 30, 2018



Charles M. Rudin, MD, PhD, chief, Thoracic Oncology Service, co-director, Druckenmiller Center for Lung Cancer Research, Sylvia Hassenfeld Chair in Lung Cancer Research, Memorial Sloan Kettering Cancer Center, discusses the success of immunotherapy in small cell lung cancer (SCLC).

This is an exciting time for SCLC, Rudin says, as new targets are emerging and new strategies are being deployed. One of the recent successes was with the PD-L1 inhibitor atezolizumab (Tecentriq). In patients with extensive-stage SCLC, the addition of atezolizumab to standard carboplatin and etoposide in the frontline setting significantly prolonged survival compared with the chemotherapy regimen alone, according to findings from the IMpower133 trial.

The global, double-blind, randomized, placebo-controlled phase I/III IMpower133 study showed a clinically meaningful improvement in overall survival over the current standard of care for these patients. Rudin says although this is a positive study, the duration of response was not very long. There is still work being done to extend benefit though, and trials are ongoing, he adds.
SELECTED
LANGUAGE


Charles M. Rudin, MD, PhD, chief, Thoracic Oncology Service, co-director, Druckenmiller Center for Lung Cancer Research, Sylvia Hassenfeld Chair in Lung Cancer Research, Memorial Sloan Kettering Cancer Center, discusses the success of immunotherapy in small cell lung cancer (SCLC).

This is an exciting time for SCLC, Rudin says, as new targets are emerging and new strategies are being deployed. One of the recent successes was with the PD-L1 inhibitor atezolizumab (Tecentriq). In patients with extensive-stage SCLC, the addition of atezolizumab to standard carboplatin and etoposide in the frontline setting significantly prolonged survival compared with the chemotherapy regimen alone, according to findings from the IMpower133 trial.

The global, double-blind, randomized, placebo-controlled phase I/III IMpower133 study showed a clinically meaningful improvement in overall survival over the current standard of care for these patients. Rudin says although this is a positive study, the duration of response was not very long. There is still work being done to extend benefit though, and trials are ongoing, he adds.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Year in Review™: Reflecting on Recent Evidence With an Eye to the Future of Lung Cancer ManagementMar 30, 20191.5
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x